These studies indicate that administration of low-dose cisplatin and gemcitabine is safe and feasible in bladder cancer patients with impaired renal function and shows adequate levels of efficacy.

Bladder cancer is one of the more common cancers worldwide ... with one-hour bladder dwell time for each drug. Initial results with gemcitabine (Gem) and mitomycin C (MMC) appeared promising but ...

The gemcitabine and cisplatin combination has ... chemotherapy regimen in elderly patients with muscle-invasive bladder cancer. Notwithstanding all of the above considerations, many have indicated ...

For patients with advanced or metastatic pancreatic cancer, gemcitabine is the standard therapy; however, although gemcitabine therapy increases overall survival, response rates are low.

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive ...

Source: Getty Images Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder cancer, according to Thomas Powles ... to receive ...